Lyrica Pregabalin Molecular Model #3

by Scimat

Title

Lyrica Pregabalin Molecular Model #3

Artist

Scimat

Medium

Photograph - Photograph

Description

Lyrica (Pregabalin) [(S)-3-(aminomethyl)-5-methylhexanoic acid] was approved in 2007 by the U.S. Food and Drug Administration for the treatment of fibromyalgia. Until then, Pregabalin was used to treat diabetic peripheral neuropathy, post-herpetic neuralgia, and as an additional therapy for adults with partial onset seizures. Lyrica's mode of action is not known. It is thought to work by binding to calcium channels found on nerve cells in the brain and spinal cord. This reduces the release of various neurotransmitters from these nerve cells. The effectiveness of Lyrica (300 or 450 mg/day) for treating fibromyalgia was established by two clinical trials involving 1,800 people. Lower doses (e.g. 50 mg as shown) have been used to treat severe neuropathic pain. While it may be a very beneficial drug for some patients with fibromyalgia, precautions for safe use must be followed because there are many adverse side effects. Formula C8 H17 N O2. Molecular mass 159.23 g/mol Carbon grey; Hydrogen cyan; Nitrogen blue; Oxygen red.

Uploaded

April 13th, 2016

Statistics

Viewed 1,449 Times  -  Last Visitor from Romeo, MI on 04/16/2024 at 11:57 AM

Colors

Embed

Share

Sales Sheet

Tags